AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 8th, 2005 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of January 31, 2005 (the “Execution Date”), by and between Celldex Therapeutics, Inc., a Delaware corporation (including its assignees, (the “Acquirer”), and Alteris Therapeutics, Inc., a Delaware corporation (the “Transferor”; and together with the Acquirer, each, a “Party” and, collectively, the “Parties”).
CELLDEX THERAPEUTICS, INC. (a Delaware corporation) SHARES OF COMMON STOCK (par value $0.01 per share) PURCHASE AGREEMENTUnderwriting Agreement • June 8th, 2005 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
Celldex Therapeutics, Inc., a Delaware corporation (“Celldex” or the “Company”), confirms its agreement with Janney Montgomery Scott LLC, a Pennsylvania corporation (“Janney”) and ThinkEquity Partners LLC, a limited liability company (“ThinkEquity”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any Underwriters substituted as hereinafter provided in Section ), for whom Janney and ThinkEquity are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the number of shares of the Company’s class of Common Stock, par value $0.01 per share (the “Common Stock”), set forth in Schedule A hereto (the “Initial Securities”) and (ii) the grant by the Company to the Underwriters of the option described in Section hereof to purchase all or any part of additional shares of Common Stock to
